Article

Intravenous aminobisphosphonates for managing complications of malignant osteolysis in companion animals.

Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
Topics in Companion Animal Medicine (Impact Factor: 1.16). 09/2009; 24(3):151-6. DOI: 10.1053/j.tcam.2009.02.003
Source: PubMed

ABSTRACT Aminobisphosphonates are a class of drugs effectively used for the management of pathologic skeletal conditions in people, most notably hormonally mediated osteoporosis and cancer-associated bone metastases. Based on their physicochemical properties, aminobisphosphonates concentrate within areas of active skeletal remodeling and exert protective bone biologic effects through the induction of osteoclast apoptosis. Given the similar mineral composition and cellular components of bone tissue shared among mammals, it would be expected that aminobisphosphonates should also be effective in managing malignant bone diseases in dogs and cats. The first half of this review article briefly summarizes the general properties of aminobisphosphonates including their pharmacology, mechanism of action, and potential adverse side effects. The second half of this review focuses on the clinical utility of aminobisphosphonates and measures of response in dogs and cats diagnosed with malignant skeletal tumors.

0 Bookmarks
 · 
86 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minodronate, a new nitrogen-containing bisphosphonate, was developed in Japan. It was the first drug to demonstrate significant prevention of vertebral fractures in Japanese patients with osteoporosis in a phase III doubleblind comparative study. As a result of positive data from clinical trials in Japan minodronate was granted a Japanese marketing approval for the treatment of osteoporosis on January 21, 2009. In vitro studies demonstrated that minodronate is one of the most potent inhibitors of bone resorption among currently available bisphosphonates. Preclinical studies demonstrated the inhibitory effect of minodronate on the decrease in the bone mineral density (BMD) in ovariectomized rats, dogs and monkeys. Daily oral minodronate was safe, well tolerated and effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis. The effects on lumbar and hip BMD and the safety profile of minodronate are comparable to those of alendronate. These data suggest that minodronate is a promising new potent bisphosphonate for the treatment of osteoporosis.
    Drugs of today (Barcelona, Spain: 1998) 01/2010; 46(1):33-7. · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PRACTICAL RELEVANCE: Musculoskeletal neoplasia is an uncommon but Important differential diagnosis for cats presenting with lameness, pain or swellings associated with bones and/or soft tissues. The most common tumours of soft tissue origin are the sarcomas (in particular feline injection site sarcomas [FISSs]); the most common bone tumour of the cat is osteosarcoma (OSA). CLINICAL CHALLENGES: FISSs present a clinical challenge in terms of their local invasiveness, difficulty in obtaining complete surgical excision and high risk of local recurrence. Axial and extraskeletal OSAs pose similar challenges, whereas appendicular OSA is usually easy to remove via limb amputation and can, therefore, carry a good prognosis in many cases. PATIENT GROUP: Cats of any age, gender or breed may be affected, although bone tumours predominantly affect middle- to old-aged cats. GLOBAL IMPORTANCE: Vaccination of cats is of global importance in preventing feline diseases; hence, any possible significant consequences of vaccination such as neoplasia, even of a low incidence, are of huge concern to cat owners and veterinarians alike. EVIDENCE BASE: This review is based on current literature relating to pathogenesis, pathology, presentation, diagnosis, staging, treatment and prognosis. It aims to summarise feline musculoskeletal neoplasia for clinicians in general practice.
    Journal of feline medicine and surgery. 01/2012; 14(1):43-54.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 3-year-old Ragdoll cat was referred for investigation of polyuria, polydipsia, vomiting, weight loss and hypercalcaemia. Serum biochemical abnormalities included total and ionised hypercalcaemia and hypophosphataemia. Following clinical investigations a diagnosis of idiopathic hypercalcaemia was made. Because of the severity of the hypercalcaemia and the associated clinical signs, treatment for hypercalcaemia was commenced with pamidronate. Major electrolyte abnormalities were detected but, remarkably, were accompanied by minimal clinical signs. The cat was subsequently treated with oral alendronate and is clinically normal 15 months later. Reports of the use of bisphosphonates in cats are limited and close monitoring of patients is recommended.
    Journal of Feline Medicine & Surgery 10/2010; 13(2):129-134. · 1.22 Impact Factor